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Effects of an Antibiotic Cycling Program on Antibiotic Prescribing
Practices in an Intensive Care Unit
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Various interventions have been proposed to combat the increase of antibiotic resistance and influence
antibiotic prescribing practices. A prospective cohort study in a medical intensive care unit was conducted to
determine the effect of an antibiotic cycling program on patterns of antibiotic use and to determine patient
factors associated with cycling adherence. Four major classes of antibiotics for empirical therapy of suspected
gram-negative bacterial infections were rotated at 3- and 4-month intervals. During the study, 1,003 patients
received antibiotic therapy with at least one of the study drugs; of the 792 receiving cycle antibiotics during the
cycling period, 598 (75.5%) received an on-cycle drug. Compared to the baseline, cycling recommendations
increased the use of the target cycle agent: the use of cephalosporins increased during cycle 1 (56 to 64% of total
antibiotic days, P < 0.001), fluoroquinolone use increased in cycle 2 (24 to 55%, P < 0.001), carbapenem use
increased during cycle 3 (14 to 38%, P < 0.001), and use of extended-spectrum penicillins increased in cycle
4 (5 to 36%, P < 0.001). Overall, 48% of total cycle antibiotic days were compliant with the cycling protocol.
On average, 8.8 days per patient were spent receiving on-cycle drugs (range, 1 to 109). Cycle periods that
specified carbapenem and fluoroquinolone use had the highest number of off-cycle days (62 and 64%).
Predictors of on-cycle antibiotic use were increased severity of illness, as measured by an acute physiology and
chronic health evaluation II score, and greater length of intensive care unit stay. In conclusion, the successful
implementation of this cycling protocol increased antibiotic heterogeneity over time in the study unit.
Antibiotic-resistant bacteria are an increasing problem in
intensive care units (ICU). Infection with antibiotic-resistant
organisms can cause increased hospital length of stay, mortal-
ity, and patient costs (18).
Multiple strategies have been employed to control the
spread of these resistant organisms. Strategies to limit antibi-
otic resistance include increased adherence to infection control
measures, therapeutic antibiotic substitution, prudent prescrib-
ing of antibiotics, and pharmacy-based computer antibiotic
management programs (6, 9, 13, 18). In addition, the cycling or
rotation of antibiotics for empirical therapy has been examined
as a method for preventing the development of antimicrobial
resistance (2, 3, 5, 8, 10, 12, 14, 15).
Data suggest that patterns of antibiotic use influence the
development of resistance (11). Mathematical modeling sug-
gests that heterogeneous antibiotic use may limit the emer-
gence of resistance (15). Some studies demonstrate that cycling
or switching of antibiotics with a gram-negative spectrum of
activity may affect antibiotic resistance patterns within the ICU
and may decrease the incidence of antibiotic-resistant gram-
negative infections and infection-related mortality (5, 12, 14).
In previous studies of antibiotic cycling, factors influencing
compliance with rotation protocols have not always been ana-
lyzed. To truly understand the impact of antibiotic cycling
programs, it is essential to demonstrate the extent of adher-
ence or compliance with the targeted antibiotic switch and to
understand the complete exposure of different classes of anti-
biotics in the study setting both at the individual patient level
and at the ICU level.
The purpose of this study was to determine the impact of
routine cycling of antibiotics for empirical therapy against
gram-negative bacteria on the overall pattern of antibiotic use
in a medical ICU (MICU). In addition, we wanted to deter-
mine the overall compliance with the antibiotic cycling regimen
in the medical ICU and to examine patient characteristics
associated with on- and off-cycle antibiotic use.
MATERIALS AND METHODS
Barnes Jewish Hospital is a 1,400-bed, urban, tertiary care, teaching hospital
located in St. Louis, Mo. The study unit is a 19-bed MICU. The MICU is a closed
unit with a multidisciplinary care team, which includes a full-time clinical phar-
macist, eight resident physicians, one pulmonary or critical care fellow, and one
attending physician, all of whom rotate on a monthly basis. All MICU attending
physicians are board certified in critical care medicine. In 2000, there were 1,290
admissions, and the mean patient length of stay was 4.6 days.
Data were prospectively collected on all patients admitted to the MICU for
more than two calendar days between 14 February 2000 and 30 June 2002. Data
collected included patient demographics, past medical history, hospital and ICU
admission dates, and acute physiology and chronic health evaluation II
(APACHE II) score upon admission (7). In addition, process of care informa-
tion, including use of mechanical ventilation, central venous catheter use, and
enteral nutrition data, was collected. Data pertaining to ICU treatment and
events, including organ failure and acquisition of Clostridium difficile-associated
diarrhea were recorded. All definitions were selected prospectively as part of the
original study design. The definitions for organ dysfunction were those originally
described by Rubin and colleagues (17).
Baseline data were collected for 4.5 months (14 February to 30 June 2000).
During this period, the prescription of antibiotics for the empirical coverage of
presumed infections by gram-negative bacteria was at the discretion of the
ordering physician. Barnes Jewish Hospital has an antibiotic management pro-
gram, staffed by two full-time clinical pharmacists and infectious disease fellows.
During the baseline period, all antibiotic classes with broad-spectrum activity
against gram-negative bacteria (i.e., expanded-spectrum and “fourth-generation”
* Corresponding author. Mailing address: Division of Infectious
Diseases, Washington University School of Medicine, Box 8051, 660 S.
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cephalosporins [e.g., cefepime], fluoroquinolones, and carbapenems and extend-
ed-spectrum penicillins) required approval by the hospital antibiotic manage-
ment program prior to being dispensed. The only exception to this was cefepime,
which could be prescribed for 72 h. After 72 h, the ordering physician had to get
approval from the antibiotic management program for continued use of the drug.
After the baseline observation period, an antibiotic cycling protocol was then
implemented which used four antibiotic classes with gram-negative activity for
empirical use cycled every 3 to 4 months over a 2-year period. The four antibiotic
classes that were cycled included cephalosporins, fluoroquinolones, carbapen-
ems, and extended-spectrum penicillins. The cycle algorithm was developed with
data from current MICU antimicrobial resistance profiles. This four-drug rota-
tion was cycled twice, with the cycle drug changing every 4 months during the first
year (rotation 1) and every 3 months during the second year (rotation 2) (Table
1).
On-cycle drug use was defined as use of the cycle antibiotic class during its
assigned cycle period. An antibiotic was considered off cycle if an antibiotic class
in the cycle protocol was ordered outside its scheduled time period (e.g., cipro-
floxacin ordered during the extended-spectrum penicillin cycle). If an ICU stay
crossed over a cycle end date, the antibiotic use was considered on cycle if the
patient was kept on the cycle drug as determined by their ICU admission date.
Patient level data were dichotomized into on- and off-cycle classifications ac-
cording to the receipt of cycle antibiotics by the patient during the ICU stay.
Patients given any on-cycle antibiotics were considered on cycle, whereas pa-
tients receiving only off-cycle antibiotics were categorized as off cycle. The per-
centage of total antibiotic days on cycle and the number of patients receiving any
on-cycle antibiotics were the outcomes of interest in this analysis.
Under the direction of the MICU medical director, clinical pharmacists were
responsible for promoting this system to guide antibiotic therapy for patients by
using the chosen clinical cycling algorithms. MICU medical staff were educated
about the cycling protocol and scheduled antibiotic changes through the use of
posters, scheduled in-services, and staff meetings.
Orders for all antibiotic classes in the cycle protocol were reviewed daily by a
clinical pharmacist and, in cases of empirical treatment, were automatically
changed to the cycle antibiotic unless contraindicated (i.e., significant drug al-
lergy or identification of a resistant target pathogen). Use of the cycle antibiotic
was also encouraged for known pathogens if they were sensitive to the antibiotic.
Statistical analysis was performed by using SPSS, version 11.0, for Windows
(SPSS, Inc., Chicago, Ill.). Categorical variables were compared by using the
chi-square test or Fisher’s exact test, as appropriate. Wilcoxon rank sum tests
were utilized to compare continuous variables. The Bonferroni correction was
used in univariate analysis to adjust for multiple comparisons, and a P value of
0.05 upon two-tailed testing was considered significant. Multivariate analysis
was performed by using logistic regression. Variables considered for inclusion in
multivariate analysis had a P value of less than 0.1 in univariate analysis after
Bonferroni correction; variables were included in the final multivariate analysis
if significant in the logistic regression model (1). To account for colinear vari-
ables, multiple models were run and the model with the highest log likelihood
value was retained as the best explanatory model.
The Institutional Review Boards at both Washington University and Saint
Louis University approved this study.
RESULTS
During the study period, 3,239 patients were admitted to the
MICU; 1,172 (36%) were eligible for and enrolled in the study
(MICU length of stay greater than 48 h) (Fig. 1). Of those
enrolled, 1,003 patients (86%) received at least one of the cycle
antibiotics. Data were collected for 242 patients during the
baseline period; of these, 211 (87%) received one or more of
the study antibiotics. Among the 792 patients who received a
cycle antibiotic during the cycling period, 598 (75.5%) received
an antibiotic defined as on cycle, 499 (63%) were given one or
more off-cycle antibiotics, 293 (37%) received only on-cycle
antibiotics, 194 (24%) were given only off-cycle antibiotics, and
305 (39%) received a combination of on- and off-cycle drugs
(Fig. 1). Cycling protocol compliance as a function of total
antibiotic days was 5,300 of 10,957 (48%). On average, 8.8 days
per patient were spent taking on-cycle drugs (range, 1 to 109).
On-cycle antibiotics started in one cycle period and continued
into the next cycle time period accounted for 156 of the 5,300
(3%) on-cycle days. Cycles in which carbapenems and fluoro-
quinolones were the antibiotic class of choice had the greatest
percentage of off-cycle antibiotic use (off-cycle antibiotics were
used on 62 and 64% of total antibiotic days, respectively)
(Table 2).
Of the seven patients requiring a prescription change during
the cycling period, six (86%) were due to an inadequate cov-
erage of a known pathogen. There were no definite adverse
events (e.g., allergic reaction) related to antibiotic use, al-
though there were three suspected allergic reactions and one
suspected case of acute renal failure, possibly attributable to
antibiotics.
Cycling recommendations influenced physician prescribing
practices. Cephalosporins were the gram-negative antibiotic
class of choice during the baseline period, but in all of the cycle
periods, the designated on-cycle drug was used in the greatest
quantity (Fig. 2).
Cephalosporin use increased during cycle 1 compared to the
baseline (from 56% of the baseline to 64% of total antibiotic
days, P  0.001). Compared to the baseline, fluoroquinolone
use increased in cycles 2 and 6 (from 24 to 55%, P 0.001, and
from 24 to 41%, P  0.001, respectively).
In both cycles 3 and 7, the use of carbapenems increased
TABLE 1. Cycling protocol for empirical gram-negative
antibiotic use






Baseline None 4.5 242
1 1 Cephalosporins 4 201
2 Fluoroquinolones 4 158




2 5 Cephalosporins 3 111
6 Fluoroquinolones 3 99
7 Carbapenems 3 107
FIG. 1. Description of antibiotic use among study participants.
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compared to the baseline period (from 14 to 38%, P  0.001,
and from 14 to 40%, P  0.001, respectively).
Extended-spectrum penicillin use increased significantly
from 5% in the baseline period to 36% during cycle 4 (P 
0.001). A comparison of patients receiving on-cycle antibiotics
to other patients in the cohort is shown in Table 3. Baseline
patient characteristics associated with on-cycle antibiotic use
include congestive heart failure (P  0.03) and increased
APACHE II score (P  0.01).
Process of care events related to on-cycle antibiotic use
include sucralfate use (P  0.04). On-cycle antibiotic use was
also associated with a longer length of ICU stay (P  0.001).
Length of ICU stay, APACHE II score, and use of H2
blockers were included in the final multivariate model and
independently associated with having received on-cycle antibi-
otics. Adjusted odds ratios for included variables were signif-
icant in the final model (Table 3).
DISCUSSION
In this prospective cohort study of MICU patients, we found
that empirical antibiotic prescribing practices were influenced
by an antibiotic cycling protocol. Compared to the baseline,
cycling recommendations influenced prescribing in all seven of
the cycles. The on-cycle drug was prescribed in the greatest
quantities during its respective cycle(s), representing a signif-
icant change from baseline numbers. While a significant num-
ber of antibiotic days were considered off cycle, 64% of the
study population was still exposed to on-cycle drugs during the
cycling period. As shown in Fig. 2, successful implementation
of this cycling protocol contributed to antibiotic heterogeneity
over time in the study unit.
Predictors of on-cycle antibiotic use were increased severity
of illness and increased length of ICU stay. In addition, the use
of H2 blockers was significantly associated with not receiving
on-cycle antibiotics. All are indicators of increased severity of
illness and could explain the need for multiple antibiotics,
therefore increasing the likelihood of getting the appropriate
drug. In addition, a longer stay in the ICU will increase the
likelihood of receiving an on-cycle antibiotic.
Cooperation from the unit medical director and the MICU
medical and pharmacy staff were essential for the success of
this project. Without staff buy in, effective implementation of a
cycling protocol would be impossible. While cycling of antibi-
otics to decrease antimicrobial resistance has been studied
previously (2, 12), issues of compliance with the protocol have
not been addressed in a consistent manner. The clear defini-
tion and designation of antibiotic classes as either on or off
cycle, as established by a predetermined cycling protocol and
time parameters, allow for the quantitative analysis of the
cycling protocol implementation in our study.
Due to multidrug therapies for different infections and other
treatment situations, drug use at the patient level was not
always clearly on or off cycle. Patients could receive both on
and off-cycle antibiotics during their MICU stay, adding to the
complexity of the data analysis. Patients could be grouped by
any on-cycle drug use, any off-cycle drug use, or receipt of both
on- and off-cycle drugs. In addition, data were examined at the
unit level by using on- and off-cycle antibiotic days to compare
the sheer volume of empirical antibiotic use in the MICU. The
ability to examine the data in these various ways adds to the
strength of the analysis.
The level of cycling compliance with the antibiotic rotation
schedule was examined by Raymond et al. (16). In this study,
the use of antibiotics to treat infection was classified into one
of four compliance categories: three indicated acceptable an-
tibiotic prescribing and the fourth represented an unacceptable
deviation from the rotation protocol. The authors reported
that only 3% of antibiotic therapy was unacceptable. Limita-
tions to this analytical approach include the small sample size
of antibiotics actually examined. Only patients with infections
were included in the cohort; therefore, not all antibiotic use in
the study unit was examined.
Moss et al. examined compliance by totaling the amount of
TABLE 2. Description of off-cycle gram-negative antibiotic use per cycle period
Cycle
no. Cycle drug class
No. (%) of off-cycle drug days for: No. of off-cycle days/total
no. of cycle days (%)Cephalosporin Fluoroquinolone Carbapenem ESa penicillin
1 Cephalosporins 426 (49) 330 (38) 112 (13) 868/2,424 (36)
2 Fluoroquinolones 340 (50) 287 (43) 48 (7) 675/1,489 (45)
3 Carbapenems 546 (48) 512 (45) 75 (7) 1,133/1,817 (62)
4 ES penicillins 307 (40) 359 (46) 110 (14) 776/1,204 (64)
5 Cephalosporins 406 (66) 144 (24) 61 (10) 611/1,353 (45)
6 Fluoroquinolones 330 (49) 282 (42) 57 (9) 669/1,128 (59)
7 Carbapenems 554 (60) 346 (37) 25 (3) 925/1,542 (60)
a ES, extended spectrum.
FIG. 2. Percentage of gram-negative antibiotic use in days per cycle
period. ES, extended spectrum; Carbapen or Carbap, carbapenem;
Cephalosp or Ceph, cephalosporin; Fluoro, fluoroquinolone; ESP, ex-
tended-spectrum penicillin.
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each antibiotic used per month in the study unit in standard-
ized units and then rated the application as either pro or con
antibiotic cycling use (12). Pro use supported the cycling reg-
imen, whereas con use was detrimental to the impact of the
regimen. Pro use or cycling compliance in the various cycles
ranged from 8 to 82%, indicating that physician prescribing
preferences influenced compliance. In their cycling study, Ger-
ding and colleagues were able to effectively alter aminoglyco-
side use by changing the formulary in a controlled Veterans
Affairs Medical Center setting and to also influence antibiotic
resistance (5). Changes in the hospital formulary were imple-
mented to ensure cycling success, and the antibiotic rotations
were strictly enforced. Compliance was tracked as the percent-
age of cycle antibiotic usage by cycle period. Due to vast
differences in cycle lengths and the lack of a preset protocol,
conclusions about ideal cycling conditions are hard to obtain
(4). In other cycling studies, only the impact of the cycling and
not the actual success of the implementation of cycling are
addressed (2).
Certain limitations exist in our study design. In the first four
cycles (rotation 1), cycles were 4 months in length. During
rotation 2, cycles were 3 months in length. While this change
might shed light on the question of appropriate cycle length for
a successful cycling protocol, it also limits the generalizability
of the data. Due to project funding limitations, there was only
one cycle of extended-spectrum penicillins. In addition, the
study unit has a dedicated clinical pharmacist, a resource many
ICUs do not have. While compliance to the cycling protocol
was voluntary on the part of the physician, off-cycle orders
were often automatically changed by the pharmacist if not
contraindicated.
Baseline physician prescribing practices of antibiotics with
gram-negative activity were a strong predictor of cycling pro-
tocol prescribing practices. Baseline practices were influenced
in part by the hospital formulary restrictions and prior ap-
proval requirements of the antibiotic management team. There
were multiple patient-specific variables associated with on-cy-
cle antibiotic use, and empirical antibiotic cycling recommen-
dations did influence antibiotic ordering practices. In every
cycle except for one, cephalosporins were the most frequent
TABLE 3. Analysis of factors associated with on-cycle antibiotic use during ICU stay
Variablec On-cycle drug use(n  598)
Off-cycle drug use
(n  194) P value aOR (95% CI)
b
Patient characteristics
Mean age (yrs) (range) 59.1 (17–101) 59.4 (16–97) 0.78
Caucasian 357 (59.7) 130 (67) 0.09
Male gender 296 (49.5) 95 (49) 0.89
CHF 114 (19.1) 24 (12.4) 0.03
COPD 165 (27.6) 57 (29.4) 0.63
Cancer 86 (14.4) 20 (10.3) 0.15
Chemotherapy 12 (2) 3 (1.5) 0.48
HIV 14 (2.3) 4 (2.1) 0.54
Diabetes 210 (35.1) 62 (32) 0.42
Cirrhosis 47 (7.9) 14 (7.2) 0.77
Chronic renal failure 162 (27.1) 43 (22.2) 0.17
Dialysis 64 (39.8) 13 (30.2) 0.25
Bone marrow transplantation 33 (5.5) 12 (6.2) 0.73
Surgery in last 28 days 40 (6.7) 18 (9.3) 0.23
Mean APACHE II score(range) 24.4 (5–44) 22.9 (6–45) 0.01a 1.03 (1.01–1.05)
Processes of care
Antacid use 96 (16.1) 31 (16) 0.98
H2 histamine antagonist 256 (42.8) 96 (49.5) 0.10 0.71 (0.51–0.98)
Sucralfate use 19 (3.2) 1 (0.5) 0.04
Vasopressor use 294 (49.2) 85 (43.8) 0.16
Corticosteroid use 220 (36.8) 71 (36.6) 0.96
Enteral nutrition 381 (63.7) 115 (59.3) 0.27
Mechanical ventilation 470 (78.6) 149 (76.8) 0.60
Reintubation 112 (18.7) 25 (12.9) 0.06
ICU-related events
Tracheostomy in ICU 81 (13.5) 20 (10.3) 0.24
Mean length of ICU stay (days) (range) 10.0 (3–64) 7.6 (3–37) 0.01a 1.04 (1.02–1.07)
Acute hepatic failure 138 (23.1) 38 (19.6) 0.31
Respiratory failure 473 (79.1) 149 (76.8) 0.50
Acute renal failure 297 (49.7) 86 (44.3) 0.19
Acute CHF 111 (18.6) 31 (16) 0.42
Coma or seizure 60 (10) 14 (7.2) 0.24
C. difficile-associated diarrhea 53 (8.9) 12 (6.2) 0.24
a Significant P value after correction for multiple comparisons.
b aOR, adjusted odds ratio; 95% CI, 95% confidence interval.
c Variables considered for inclusion but not significant in the final model include congestive heart failure (CHF), sucralfate use, and reintubation. COPD, chronic
obstructive pulmonary disease; HIV, human immunodeficiency virus. Unless otherwise noted, values are numbers of patients with percentages of the total number of
patients in parentheses.
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off-cycle drug to be prescribed (Fig. 2). The ability to order
cefepime for up to 72 h before getting approval from the
antibiotic management team possibly encouraged its use. In
the baseline and all of the cycles, cephalosporin use repre-
sented greater than 20% of all cycle antibiotic use. Also, a
statistically significant reduction in the use of an antibiotic may
not be ecologically significant. The high level of cephalosporin
use in all cycles may provide enough selective pressure to
promote resistance during the off-cycle periods.
Additional data analysis will be conducted to determine the
implications and outcomes of this cycling intervention. Out-
comes, including resistance patterns of gram-negative isolates
collected during the study period and infection rates, will be
explored in future reports.
We showed that a focused antibiotic cycling program could
result in substantial changes in prescribing practices among
physicians in an academic ICU setting. This is an important
step in testing the validity of antibiotic cycling as a way of
preventing the emergence of antimicrobial resistance.
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